HIF-2α inhibitor belzutifan significantly reduces progression of clear cell renal cell carcinoma

Reviewed by Danielle Ellis, B.Sc.Oct 24 2023 The trial, led by Toni K. Choueiri, MD, Director of the Lank Center for Genitourinary Cancer at Dana-Farber Cancer Institute, showed the risk of progression was reduced by 25-26%.

Belzutifan, a HIF-2α inhibitor, is currently approved for patients with Von Hippel-Landau disease-associated renal cell carcinoma, a form of kidney cancer. The drug was originally investigated and approved for kidney cancer patients with VHL disease because they have inherited a mutation that inactivates the VHL gene, which results in an overabundance of HIF-2α in cells.

Toni K. Choueiri, MD, Director of the Lank Center for Genitourinary Cancer at Dana-Farber Cancer Institute

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Revolutionary approach links protein analysis and single-cell study to uncover disease mechanismsIntegrated liquid-biopsy proteomics with single-cell transcriptomics from ocular cell types.
Source: NewsMedical - 🏆 19. / 71 Read more »

ESMO: PARP inhibitor plus immunotherapy lowers risk of endometrial cancer progression over chemotherapy aloneImmunotherapy with the anti-PD-L1 monoclonal antibody durvalumab improved progression-free survival (PFS) in patients with newly diagnosed advanced or recurrent endometrial cancer compared with chemotherapy alone, with further benefits gained from the addition of the PARP inhibitor olaparib in maintenance setting, according to researchers from The...
Source: medical_xpress - 🏆 101. / 51 Read more »

Dad desperate to see his children grow up after crash exposed tumourGlenn Utteridge is raising funds for treatment in Japan, an adoptive cell immunotherapy in order to extend his life
Source: NorthamptonUK - 🏆 99. / 51 Read more »